- Open Access
Development of a self-replicating plasmid system for Mycoplasma hyopneumoniae
© Maglennon et al.; licensee BioMed Central Ltd. 2013
- Received: 23 April 2013
- Accepted: 10 July 2013
- Published: 29 July 2013
Mycoplasma hyopneumoniae is a prevalent swine respiratory pathogen that is a major cause of economic loss to pig producers. Control is achieved by a combination of antimicrobials, vaccination and management practices, but current vaccines offer only partial control and there is a need for improved preventative strategies. A major barrier to advances in understanding the pathogenesis of M. hyopneumoniae and in developing new vaccines is the lack of tools to genetically manipulate the organism. We describe the development and optimisation of the first successful plasmid-based system for the genetic manipulation of M. hyopneumoniae. Our artificial plasmids contain the origin of replication (oriC) of M. hyopneumoniae along with tetM, conferring resistance to tetracycline. With these plasmids, we have successfully transformed M. hyopneumoniae strain 232 by electroporation, generating tetracycline resistant organisms. The persistence of extrachromosomal plasmid and maintenance of plasmid DNA over serial passages shows that these artificial plasmids are capable of self-replication in M. hyopneumoniae. In addition to demonstrating the amenability of M. hyopneumoniae to genetic manipulation and in optimising the conditions necessary for successful transformation, we have used this system to determine the minimum functional oriC of M. hyopneumoniae. In doing so, we have developed a plasmid with a small oriC that is stably maintained over multiple passages that may be useful in generating targeted gene disruptions. In conclusion, we have generated a set of plasmids that will be valuable in studies of M. hyopneumoniae pathogenesis and provide a major step forward in the study of this important swine pathogen.
- Homologous Recombination
- oriC Region
- Mycoplasma Species
- Friis Medium
Bacteria in the genus Mycoplasma are characterised by their lack of a cell wall, small genome size and utility in synthetic biology. They are responsible for a number of important diseases in humans and other animals. Among the most important species is Mycoplasma hyopneumoniae that is the cause of enzootic pneumonia, a chronic swine respiratory disease of global economic importance to pig producers . Partial control of M. hyopneumoniae is achieved by a combination of management practices, antimicrobials and immunisation with commercially available vaccines . Although current vaccines improve performance parameters and reduce the severity of lung lesions, there is a need for more effective vaccines, particularly in response to concerns regarding the current over-use of antimicrobials in production animals. Progress in understanding the molecular basis of M. hyopneumoniae pathogenesis is essential for improved intervention measures such as vaccine development, but this has been severely hampered by the lack of tools to genetically manipulate the organism . Such tools may prove valuable in identifying and studying determinants of virulence in the mycoplasma genome that are central to the ability of the organism to cause disease. Some advances have been made with other mycoplasmas using transposon mutagenesis to generate random insertional mutants that can be screened for the expression of virulence factors using in vivo or in vitro model systems [3–9]. Such techniques have not been reported to date for M. hyopneumoniae. Additionally, transposon mutagenesis techniques produce random insertions into the mycoplasma genome, thus it can be difficult to isolate mutants with disruptions in particular genes of interest. A few mycoplasmas have also been transformed with artificial plasmids that are capable of self-replication [10–14]. These plasmids contain the origin of replication (oriC) of the mycoplasma along with an antimicrobial resistance gene cassette to facilitate genetic selection. Following transformation, these plasmids are initially replicated extrachromosomally, but can undergo integration into the host cell chromosome by recombination, owing to homology between the plasmid oriC and the oriC of the mycoplasma chromosome. In addition to demonstrating the amenability of mycoplasmas to genetic manipulation, in some cases oriC-based plasmids have been useful in promoting the generation of mutations in target genes by homologous recombination [11, 12]. Plasmid stability can be increased by reducing the size of the plasmid oriC to the minimum that is functional, therefore reducing the likelihood of incorporation of the plasmid by homologous recombination into the host chromosome [11, 12]. DNA sequences homologous to genes of interest in the mycoplasma genome could then be incorporated into the plasmid, and used to promote homologous recombination at specific sites in the mycoplasma chromosome.
In this study, a simple oriC-based plasmid system was developed as a method of determining the susceptibility of M. hyopneumoniae to transformation and optimising the conditions necessary for transformation. Requiring only the M. hyopneumoniae origin of replication and a suitable antimicrobial selection marker, we anticipated that such simple plasmids would be more likely to achieve successful transformation than, for example, a transposon mutagenesis system that also requires successful transposition into the host cell chromosome. The ability to transform M. hyopneumoniae has been long anticipated. Here we describe the generation of an oriC-based system for M. hyopneumoniae that facilitates the genetic transformation of this important pathogen.
Bacterial strains and culture
Mycoplasma hyopneumoniae strain 232  was grown in Friis medium as described by Kobisch and Friis . Liquid cultures were grown at 37 °C in a static incubator in airtight culture tubes. For growth on solid medium, a final concentration of 0.8% w/v purified agar was added to Friis medium and plates were incubated at 37 °C with 5% CO2. Colonies were visualised by light microscopy at ×35 magnification using a stereoscopic microscope. For the selection of transformed M. hyopneumoniae, tetracycline hydrochloride (Sigma-Aldrich Ltd, Gillingham, UK) or puromycin dihydrochloride (Sigma-Aldrich Ltd, Gillingham, UK) were added to a final concentration of 0.2–2.0 μg/mL and 5 μg/mL respectively. For molecular cloning, Escherichia coli strain DH5α (Invitrogen Ltd, Paisley, UK) was grown in Luria-Bertani medium containing 50 μg/mL ampicillin at 37 °C with shaking at 220 rpm. For the selection of organisms expressing the tetracycline resistance gene, tetM, 5 μg/mL tetracycline hydrochloride was also added to solid medium.
Transformation of M. hyopneumoniae
Mycoplasma hyopneumoniae strain 232 was grown in liquid culture until mid/late logarithmic phase (~108 CFU/mL), as determined by an acid colour change in the phenol red pH indicator. Cells were collected by centrifugation at 9000 × g at 4 °C for 10 min and were washed three times in an equivalent volume of electroporation buffer (272 mM sucrose, 8 mM HEPES, pH 7.4). After the final wash cells were re-suspended in electroporation buffer such that 100 μL cells was equivalent to approximately 2 mL of mycoplasma culture. Mycoplasmas were incubated on ice with plasmid DNA for 30 min and then transferred to a pre-chilled 0.2 cm electroporation cuvette (Bio-Rad Ltd, Hemel Hempstead, UK). Electroporation was performed using a Gene Pulser system (Bio-Rad Ltd, Hemel Hempstead, UK). Standard electroporation conditions were 2.5 kV, 100 Ω and 25 μF. Immediately after electroporation, 900 μL chilled Friis medium were added. After incubation for a further 15 min on ice, cells were transferred to a microcentrifuge tube and incubated for a further 3 h at 37 °C. Cultures were then plated onto solid Friis medium containing 0.2–2.0 μg/mL tetracycline and were incubated at 37 °C in 5% CO2 for 10–14 days.
Oligonucleotide sequence (5′ - 3′)
M. hyopneumoniae strain 232 oriC- i
F - AGGCCATGG TTGTTAATTATTGCTTGAAATTC
R - AGTACTAGT AAACTTTATAGGAAAGTTCG
M. hyopneumoniae strain 232 oriC- ii
F - GATGCCATGG TTGGTTGATAAGTTCGCTTC
R - GTAGACTAGT CATTCTTTCAATTTGTCATTC
M. hyopneumoniae strain 232 oriC- iii
F - GATGCCATGG TTGGTTGATAAGTTCGCTTC
R - GCTCACTAGT GACAATCAGTTTAAAAATTCAC
M. hyopneumoniae strain 232 oriC- iii
F - GCAGGACGTC TTGGTTGATAAGTTCGCTCC
R - GACGCCATGG GACAATCAGTTTAAAAATTCAC
M. hyopneumoniae strain 232 oriC- iv
F - GCATCCATGG ATATTGTGCATGCCCGCGGATAT
R - GTAGACTAGT CATTCTTTCAATTTGTCATTC
M. hyopneumoniae strain 232 oriC- v
F - GCAGGACGTC TTGGTTGATAAGTTCGCTCC
R - CGTACCATGG CCTAATTTGCTGTGTTCTAA
tetM + spiralin promoter from plasmid pSRT2
F - TAACTGCAG CAAAAGCTTGCATGCCTGCA
R - GTCACTAGT CAGTTCAGATCTTTATATAAC
tetM from plasmid pIVT
F - ATCTACTAGT CATGTGATTCTAAAGTATCC
R - GATCTGCAG CTTATTTAACAAGAAACC
tetM (without promoter) from plasmid pSRT2
Bam HI/Pst I
F - GAACTGCAGGATCC ATGGAGGAAAATCACATGA
R - CCCGGTCGACTTATATAACAACTTAAATTAC
M. hyopneumoniae strain 232 P97 promoter
F - GAATGGATCCCCAACAATTCCGGCAGTC
R - GCTAACTAGT ACGGGGATTTAAAACAGAAAC
M. hyopneumoniae strain 232 ldh promoter
F - GGCTAACTAGT ATAGAATTTTGCAATTAAAG
R - CTTAGGATCC ATTTATACTCGTATTTGTTAT
M. hyorhinis oriC
F - GACTCCATGG TCGGAATCGAGATTCCTAATT
R - GCCTACTAGT CTACACCTTCGATTTCTCTAA
M. pulmonis oriC
F - ATTAGCCATGG CACTCTGGTCAGCGCTAGATC
R - TCGCGCTAGC CTAACTTGAAAATAAGCTCC
M. conjunctivae oriC
F - GATACCATGG TATGCCTTTGGTCTAGGATG
R - CGATGTCTAGA CCCTTGAACAAATATACCA
M. ovipneumoniae oriC
F – AGTCCATGGTCAATTATTGCTTGGAATTC
R - CGTACTAGTAAACTTTATAAGAAAGTTCGCT
bla gene (DIG-labelled probe)
F – CCAATGCTTAATCAGTGAGG
R - GTATGAGTATTCAACATTTCCG
tetM (DIG-labelled probe)
F – GTGGACAAAGGTACAACGAG
R - CGGTAAAGTTCGTCACACAC
Total DNA was extracted from 20 mL mycoplasma broth culture using a Qiagen DNA Blood & Tissue kit (Qiagen Ltd, Manchester, UK) and 1 μg was digested to completion with Hin dIII. DNA was separated by electrophoresis on 0.8% agarose and blotted onto Hybond-N + membrane (GE Healthcare Ltd, Little Chalfont, UK) using standard methods . DNA was fixed to the membrane by exposure to UV light. DIG-labelled probes specific for the bla ampicillin resistance gene of pGEM-T or the tetM gene were generated from PCR-amplified DNA (see Table 1 for oligonucleotide sequences) using a DIG-High Prime DNA Labelling and Detection Starter Kit II (Roche Applied Science Ltd, Burgess Hill, UK). The same kit was used to perform pre-hybridisation and hybridisation in accordance with the manufacturers instructions. The membrane was autoradiographed at room temperature using CL-XPosure Film (Fisher Scientific Ltd, Loughborough, UK).
Generation of M. hyopneumoniae transformants
In our initial attempts at transforming M. hyopneumoniae, we constructed a simple plasmid containing the predicted oriC region of M. hyopneumoniae strain 232 and tetM conferring resistance to tetracycline. A large 2.1 kbp region of the M. hyopneumoniae strain 232 genome encompassing the entire dnaA gene and upstream and downstream AT-rich regions was selected. Homologous DNA sequences of other mycoplasmas demonstrating a similar gene arrangement have shown success in functioning as an oriC in artificial self-replicating plasmids [9, 11]. The tetM gene has been used as a selection marker for mycoplasmas [10, 12] and we confirmed the sensitivity of M. hyopneumoniae strain 232 to tetracycline. Following the methods of Hannan , the minimum inhibitory concentration (MIC) of tetracycline was 0.03 μg/mL in liquid medium and 0.015 μg/mL in solid medium. Following the transformation of M. hyopneumoniae strain 232 with 10 μg of pMHO-1, cells were incubated for 3 h at 37 °C and then plated onto Friis agar containing 2 μg/mL tetracycline. Triplicate repeats were performed and after 14 days incubation, no growth was observed for pMHO-1 or “no DNA” controls. We considered that the tetM promoter sequence may be inactive in M. hyopneumoniae and/or that the tetracycline concentration may be too high to be overcome by transformed organisms. The tetM sequence under control of its own promoter, as derived from Enterococcus faecalis, is expressed at levels sufficient to confer tetracycline resistance in several mycoplasmas [12, 23–25]. However, other mycoplasmas may require an alternative promoter sequence, such as the spiralin gene promoter of Spiroplasma citri that has be shown to be active in several mycoplasma species [11, 13, 14]. In addition to constructing pMHO-2 utilising tetM and the spiralin gene promoter sequence, we produced plasmids pMHO-3 and pMHO-4 containing tetM with the putative promoter regions of the M. hyopneumoniae strain 232 P97 ciliary adhesin gene  and lactate dehydrogenase (ldh) gene respectively. In addition to altering the promoter sequences controlling tetM expression, we sought to determine whether or not a lower concentration of tetracycline would enhance the growth of transformants. For other mycoplasmas, transformed cells are typically selected using concentrations of between 2 and 4 μg/mL tetracycline [12, 23, 25]. Having determined that a concentration of 0.015 μg/mL could inhibit growth of M. hyopneumoniae 232 on Friis agar, we lowered the concentration of tetracycline to 0.2 μg/mL. M. hyopneumoniae strain 232 was transformed in triplicate with plasmids pMHO-1, pMHO-2, pMHO-3 and pMHO-4 and plated onto Friis agar containing 0.2 μg/mL tetracycline. After incubation for 14 days tetracycline resistant colonies were present in bacteria transformed with all four oriC plasmids but were completely absent in the “no DNA” control, demonstrating activity of the four promoter sequences. Morphologically, colonies were identical to untransformed M. hyopneumoniae colonies, but colony growth lagged by approximately 3 days (Figure 1E). The highest number of transformants was generated using pMHO-2 (2.5 × 10-4/CFU), with fewer for pMHO-3 (5.8 × 10-5/CFU) and pMHO-1 (1.7 × 10-5/CFU), and least with pMHO-4 (8.3 × 10-6/CFU). Individual colonies were picked from agar and grown in Friis medium containing 0.5 μg/mL tetracycline, after which they were sub-cultured every 2–3 days in 1 μg/mL tetracycline. After three serial passages, plasmid DNA was extracted and separated by electrophoresis. Plasmid DNA was readily identified for each transformant whereas no plasmid DNA was seen with untransformed M. hyopneumoniae 232 (Figure 1F). However, less plasmid DNA was detected for pMHO-3 and pMHO-4 transformants. Given that both of these plasmids contain promoter sequences 400–600 bp in size that are identical to M. hyopneumoniae genomic DNA, we suspect that plasmid integration had occurred by homologous recombination.
Optimisation of transformation conditions
Effect of electroporation voltage on transformation frequency.
Average transformation frequency (transformants/CFU) [SE]
5.4 × 10-6 [1.2 × 10-6]
4.2 × 10-7 [3.9 × 10-7]
Effect of plasmid DNA concentration on transformation frequency.
Average transformation frequency (transformants/CFU) [SE]
5.6 × 10-3 [1.1 × 10-3]
5.0 × 10-3 [1.4 × 10-3]
3.3 × 10-4 [9.6 × 10-5]
2.5 × 10-4 [3.7 × 10-5]
Host species specificity of oriC regions
Suspecting that the large 2.1 kbp oriC in our plasmids would favour integration by homologous recombination, we determined whether the predicted oriC regions of four phylogenetically closely related Mycoplasma species would function in M. hyopneumoniae. We hypothesised that the oriC regions of one or more of these mycoplasmas may be sufficiently similar to that of M. hyopneumoniae to be recognised as an oriC, yet different enough that the incidence of homologous recombination would be reduced. The genomes of M. hyorhinis, M. pulmonis, M. conjunctivae and M. ovipneumoniae exhibited a similar arrangement of genes in the oriC region to M. hyopneumoniae, with AT-rich regions and DnaA boxes in the intergenic regions flanking dnaA. M. hyopneumoniae strain 232 cells were electroporated in triplicate with plasmids pMHO-2, pMhyor, pMpulm, pMconj and pMovip in two independent experiments and cultured on Friis agar containing 0.2 μg/mL tetracycline. As expected, many individual tetracycline resistant colonies were obtained with the pMHO-2 plasmid within 10 days but not for “no DNA” controls. However, after 14 days, no colonies were visible in any culture transformed with plasmids containing the oriC regions of the other Mycoplasma species.
Determination of the minimum functional oriC of M. hyopneumoniae
As an alternative strategy to reduce the incidence of homologous recombination, we attempted to reduce the size of oriC used in our plasmids. To define the minimum functional oriC in M. hyopneumoniae, initially the oriC of pMHO-2 (oriC-i) was reduced by 300 bp by removing excess DNA sequence lying upstream and downstream of the AT-rich intergenic regions (pOriC-ii). With both AT-rich regions and the dnaA gene still present, as expected, there was no reduction in transformation efficiency (Figure 2). Next, we determined whether each of the two AT-rich intergenic regions flanking the dnaA gene would function as an oriC independently. Plasmids pOriC-iii and pOriC-iv were constructed containing the upstream and downstream intergenic regions respectively. pOriC-iii contained the AT-rich region upstream of dnaA, and also extended downstream into dnaA to include three further putative DnaA boxes. M. hyopneumoniae strain 232 was transformed in triplicate with each plasmid but failed to produce any transformants. Therefore, each AT-rich region was unable to function independently as an oriC. However, by placing both intergenic regions adjacent to each other in plasmid pOriC-iii/iv, transformants were produced in all three triplicate transformations. The transformation efficiency was approximately 10-fold lower than when the entire dnaA gene was present (Figure 2). Finally, we constructed plasmid pOriC-iv/v to determine whether or not the entire dnaA gene sequence could be removed leaving the AT-rich intergenic regions alone. Following electroporation of M. hyopneumoniae strain 232 with pOriC-iv/v, tetracycline resistant colonies were generated but with a transformation efficiency approximately 100-fold lower than that achieved when the dnaA gene sequence was included (Figure 2). We concluded that the minimum oriC necessary for functionality in self-replicating plasmids was approximately 700 bp long and included both AT-rich intergenic regions lying upstream and downstream of the dnaA gene, but that the dnaA gene sequence itself was not essential to this. To determine how robust the resistance to tetracycline of pOriC-iv/v transformants was, we determined the MIC of three individual colonies in triplicate. After initial growth in 1 μg/mL, the MIC for tetracycline of all three clones in Friis broth was 32 μg/mL compared to 0.03 μg/mL for untransformed M. hyopneumoniae strain 232.
Stability of plasmid DNA
The inability to genetically manipulate M. hyopneumoniae has been a major obstacle to progress in understanding the survival and pathogenesis of the organism. Using simple artificial self-replicating plasmids containing the oriC of M. hyopneumoniae and an antimicrobial resistance gene, we have shown for the first time that the organism is susceptible to transformation. We found that the transformation conditions optimised by Hedreyda et al.  and used widely in other Mycoplasmas are suitable for M. hyopneumoniae. However, other critical factors include titration of the tetracycline concentration to a level that can readily be overcome by the TetM resistance protein, the use of high voltage for electroporation and the use of a large excess of plasmid DNA. Additionally, we found that the choice of promoter affected the expression of the tetM gene, and as is the case with other mycoplasmas, the spiralin gene promoter of Spiroplasma citri is a suitable choice for M. hyopneumoniae. Our oriC system allowed us to assess the function of putative M. hyopneumoniae promoter sequences, and confirmed the identity of two promoter sequences that were active in controlling tetM expression. The P97 promoter sequence was recently predicted and we have verified that this is functional in our plasmid system . Using the criteria identified by Weber Sde et al. , we also predicted the location of the ldh promoter, and again demonstrated its activity in our plasmid system. These M. hyopneumoniae-specific promoters will be valuable in the generation of further tools for the genetic manipulation of the organism. Using our system, we verified that the origin of replication of M. hyopneumoniae lies in the region of dnaA and includes two short AT-rich regions. It has been suspected that the oriC of M. hyopneumoniae lies in this region, but unusually within the AT-rich regions there are only two DnaA boxes that resemble the E. coli consensus sequence, whereas for other mycoplasma species, there are typically multiple DnaA boxes . Additional DnaA boxes are present within the dnaA gene, but these are not required for a functional oriC. We hypothesised that the oriC regions of mycoplasmas showing a high degree of nucleotide sequence similarity to M. hyopneumoniae would function in M. hyopneumoniae, and enable stable plasmid maintenance without integration by homologous recombination. However, it appears that oriC s are very specific to their host species and none of the oriC regions from four closely related Mycoplasma species functioned in M. hyopneumoniae.
The minimum M. hyopneumoniae sequence that functioned in an oriC plasmid (pOriC-iv/v) was approximately 700 bp in length and included both AT-rich regions. This plasmid was maintained extrachromosomally over at least 19 passages with selection pressure, equivalent to over 8 weeks post-transformation. However, when selection pressure was removed, tetracycline resistance was rapidly lost within 5 passages. Having demonstrated that plasmids carrying sequences with a high degree of homology to regions of the M. hyopneumoniae genome can undergo integration by homologous recombination, it is likely that this plasmid will be useful in generating targeted disruptions in genes of interest. By incorporating sequences encoding mycoplasma genes of interest, it is likely that we will be able to direct homologous recombination and cause disruption of these genes, as has been shown with other mycoplasmas [11, 12]. In addition to tetM, we demonstrated that pac conferring resistance to puromycin can be expressed in M. hyopneumoniae strain 232 from our oriC plasmids when driven by the spiralin gene promoter sequence of S. citri. While M. hyopneumoniae strain 232 is exquisitely sensitive to tetracycline, as demonstrated in this study, many of our recent field isolates of M. hyopneumoniae are relatively resistant (data not shown). However, these strains are susceptible to puromycin, therefore pac may be a more suitable selection marker for generating transformants in other M. hyopneumoniae isolates.
In summary, we have shown that M. hyopneumoniae is indeed susceptible to genetic manipulation by transformation with self-replicating plasmids. In doing so, we have developed a system that will undoubtedly be useful in genetic studies of M. hyopneumoniae and probably other mycoplasma species. Additionally, we anticipate that our findings will be a key step towards the development of a transposon-mediated system to generate random mutants of M. hyopneumoniae, which will take us a step closer to unraveling the pathogenesis of this poorly understood pathogen.
This work was supported by a Longer and Larger (LoLa) grant from the Biotechnology and Biological Sciences Research Council (grant numbers BB/G020744/1, BB/G019177/1, BB/G019274/1 and BB/G018553/1), the UK Department for Environment, Food and Rural Affairs and Zoetis awarded to the Bacterial Respiratory Diseases of Pigs-1 Technology (BRaDP1T) consortium (see Additional file 1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Joel Renaudin for the gift of the pSRT2 plasmid and Jaume Pinyol for the pIVT plasmid.
- Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F: Control of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol. 2008, 126: 297-309. 10.1016/j.vetmic.2007.09.008.View ArticlePubMedGoogle Scholar
- Minion FC, Lefkowitz EJ, Madsen ML, Cleary BJ, Swartzell SM, Mahairas GG: The genome sequence of Mycoplasma hyopneumoniae strain 232, the agent of swine mycoplasmosis. J Bacteriol. 2004, 186: 7123-7133. 10.1128/JB.186.21.7123-7133.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Pour-El I, Adams C, Minion FC: Construction of mini-Tn4001tet and its use in Mycoplasma gallisepticum. Plasmid. 2002, 47: 129-137. 10.1006/plas.2001.1558.View ArticlePubMedGoogle Scholar
- Cao J, Kapke PA, Minion FC: Transformation of Mycoplasma gallisepticum with Tn916, Tn4001, and integrative plasmid vectors. J Bacteriol. 1994, 176: 4459-4462.PubMed CentralPubMedGoogle Scholar
- Dybvig K, French CT, Voelker LL: Construction and use of derivatives of transposon Tn4001 that function in Mycoplasma pulmonis and Mycoplasma arthritidis. J Bacteriol. 2000, 182: 4343-4347. 10.1128/JB.182.15.4343-4347.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Hahn TW, Mothershed EA, Waldo RH, Krause DC: Construction and analysis of a modified Tn4001 conferring chloramphenicol resistance in Mycoplasma pneumoniae. Plasmid. 1999, 41: 120-124. 10.1006/plas.1998.1387.View ArticlePubMedGoogle Scholar
- Hedreyda CT, Lee KK, Krause DC: Transformation of Mycoplasma pneumoniae with Tn4001 by electroporation. Plasmid. 1993, 30: 170-175. 10.1006/plas.1993.1047.View ArticlePubMedGoogle Scholar
- Reddy SP, Rasmussen WG, Baseman JB: Isolation and characterization of transposon Tn4001-generated, cytadherence-deficient transformants of Mycoplasma pneumoniae and Mycoplasma genitalium. FEMS Immunol Med Microbiol. 1996, 15: 199-211. 10.1111/j.1574-695X.1996.tb00086.x.View ArticlePubMedGoogle Scholar
- Chopra-Dewasthaly R, Zimmermann M, Rosengarten R, Citti C: First steps towards the genetic manipulation of Mycoplasma agalactiae and Mycoplasma bovis using the transposon Tn4001mod. Int J Med Microbiol. 2005, 294: 447-453. 10.1016/j.ijmm.2004.09.010.PubMed CentralView ArticlePubMedGoogle Scholar
- Chopra-Dewasthaly R, Marenda M, Rosengarten R, Jechlinger W, Citti C: Construction of the first shuttle vectors for gene cloning and homologous recombination in Mycoplasma agalactiae. FEMS Microbiol Lett. 2005, 253: 89-94. 10.1016/j.femsle.2005.09.021.View ArticlePubMedGoogle Scholar
- Cordova CM, Lartigue C, Sirand-Pugnet P, Renaudin J, Cunha RA, Blanchard A: Identification of the origin of replication of the Mycoplasma pulmonis chromosome and its use in oriC replicative plasmids. J Bacteriol. 2002, 184: 5426-5435. 10.1128/JB.184.19.5426-5435.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee SW, Browning GF, Markham PF: Development of a replicable oriC plasmid for Mycoplasma gallisepticum and Mycoplasma imitans, and gene disruption through homologous recombination in M. gallisepticum. Microbiology. 2008, 154: 2571-2580. 10.1099/mic.0.2008/019208-0.View ArticlePubMedGoogle Scholar
- Janis C, Lartigue C, Frey J, Wroblewski H, Thiaucourt F, Blanchard A, Sirand-Pugnet P: Versatile use of oriC plasmids for functional genomics of Mycoplasma capricolum subsp. capricolum. Appl Environ Microbiol. 2005, 71: 2888-2893. 10.1128/AEM.71.6.2888-2893.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Lartigue C, Blanchard A, Renaudin J, Thiaucourt F, Sirand-Pugnet P: Host specificity of mollicutes oriC plasmids: functional analysis of replication origin. Nucleic Acids Res. 2003, 31: 6610-6618. 10.1093/nar/gkg848.PubMed CentralView ArticlePubMedGoogle Scholar
- Kobisch M, Friis NF: Swine mycoplasmoses. Rev Sci Tech. 1996, 15: 1569-1605.PubMedGoogle Scholar
- Calcutt MJ, Foecking MF, Rosales RS, Ellis RJ, Nicholas RA: Genome sequence of Mycoplasma hyorhinis strain GDL-1. J Bacteriol. 1848, 2012: 194-Google Scholar
- Chambaud I, Heilig R, Ferris S, Barbe V, Samson D, Galisson F, Moszer I, Dybvig K, Wroblewski H, Viari A, Rocha EP, Blanchard A: The complete genome sequence of the murine respiratory pathogen Mycoplasma pulmonis. Nucleic Acids Res. 2001, 29: 2145-2153. 10.1093/nar/29.10.2145.PubMed CentralView ArticlePubMedGoogle Scholar
- Calderon-Copete SP, Wigger G, Wunderlin C, Schmidheini T, Frey J, Quail MA, Falquet L: The Mycoplasma conjunctivae genome sequencing, annotation and analysis. BMC Bioinformatics. 2009, 10 (Suppl 6): S7-10.1186/1471-2105-10-S6-S7.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang F, Tang C, Wang Y, Zhang H, Yue H: Genome sequence of Mycoplasma ovipneumoniae strain SC01. J Bacteriol. 2011, 193: 5018-10.1128/JB.05363-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Algire MA, Lartigue C, Thomas DW, Assad-Garcia N, Glass JI, Merryman C: New selectable marker for manipulating the simple genomes of Mycoplasma species. Antimicrob Agents Chemother. 2009, 53: 4429-4432. 10.1128/AAC.00388-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Sambrook JJ, Russell DDW: Molecular Cloning: A Laboratory Manual. 2001, New York: Cold Spring Harbor Laboratory Press, 3Google Scholar
- Hannan PC: Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. International Research Programme on Comparative Mycoplasmology. Vet Res. 2000, 31: 373-395. 10.1051/vetres:2000100.View ArticlePubMedGoogle Scholar
- Whetzel PL, Hnatow LL, Keeler CL, Dohms JE: Transposon mutagenesis of Mycoplasma gallisepticum. Plasmid. 2003, 49: 34-43. 10.1016/S0147-619X(02)00114-2.View ArticlePubMedGoogle Scholar
- Glass JI, Assad-Garcia N, Alperovich N, Yooseph S, Lewis MR, Maruf M, Hutchison CA, Smith HO, Venter JC: Essential genes of a minimal bacterium. Proc Natl Acad Sci U S A. 2006, 103: 425-430. 10.1073/pnas.0510013103.PubMed CentralView ArticlePubMedGoogle Scholar
- French CT, Lao P, Loraine AE, Matthews BT, Yu H, Dybvig K: Large-scale transposon mutagenesis of Mycoplasma pulmonis. Mol Microbiol. 2008, 69: 67-76. 10.1111/j.1365-2958.2008.06262.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Weber Sde S, Sant’Anna FH, Schrank IS: Unveiling Mycoplasma hyopneumoniae promoters: sequence definition and genomic distribution. DNA Res. 2012, 19: 103-115. 10.1093/dnares/dsr045.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.